The annual meeting of the Association of Diabetes Care and Education Specialists (ADCES) has concluded. From August 7 through August 10, in Columbus, Ohio, ADCES26 was four days filled with networking and continuing education opportunities, educational sessions featuring real-world strategies, and research presentations on cutting-edge innovation for diabetes care and education specialists from around the world.

Today, we're taking a look at some of the poster presentations from this year's meeting. The following posters were published in the June 2026 supplement issue of Diabetes.

Ertugliflozin Mitigates Blood Pressure Increments during a High-Sodium Diet in People with Type 2 Diabetes

  • Description: Individuals with type 2 diabetes (T2D) often experience greater BP increments compared to normoglycemic individuals when consuming a high-sodium diet, a phenomenon referred to as sodium-sensitive hypertension. We hypothesized that the SGLT2i ertugliflozin could mitigate blood pressure increments during a high-sodium (HS) diet in people with T2D.
  • Conclusion: ERTU prevented the BP-increment induced by HS intake without altering sodium excretion. Mitigation of sodium sensitivity by ERTU may contribute to its beneficial cardio-kidney effects.

Bridging Omics to Phenotypes: A Deep-Learning Framework for Molecular Characterization of Type 2 Diabetes Subtypes

  • Description: Type 2 diabetes (T2D) is highly heterogeneous; accurate stratification is essential for understanding its pathophysiology and advancing precision medicine. We developed a deep learning-based framework to integrate multi-omics data and identify subtypes reflecting molecular and lifestyle factors.
  • Conclusion: Deep learning-based multi-omics integration effectively identifies clinically distinct T2D subtypes, outperforming single-omics models. This approach provides a comprehensive insight into T2D heterogeneity, supporting personalized management.

Redistribution of Insulin Resistance Uncouples Obesity from Hepatic Steatosis under Flattened Glucocorticoid Rhythms

  • Description: Flattened glucocorticoid (GC) rhythms are a hallmark of chronic stress and a driver of obesity. However, it remains unclear whether the metabolic profile of GC-flattened obesity mirrors the dysfunction of caloric excess. We determined if disrupted GC timing generates a distinct metabolic phenotype from diet-induced obesity (DIO).
  • Conclusion: Flattened GC rhythms induce a metabolically compensated obesity distinct from caloric excess. This tissue-specific reorganization uncouples adiposity from hepatic steatosis and identifies GC rhythmicity as a key regulator of cross-tissue insulin action.

Gestational Glucose Intolerance and Future Cardiovascular Disease Risk

  • Description: Gestational diabetes (GDM) increases future cardiovascular disease (CVD) risk, but the link between gestational glucose intolerance (GGI), subclinical hyperglycemia in pregnancy that does not meet criteria for GDM, and CVD is unclear. We examined the association between GGI and future CVD risk.
  • Conclusion: GGI-1 and GDM confer similar CVD risk, but this increased risk can be attributed to pre- or early pregnancy CVD risk factors.

Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Icodec in People with Type 2 Diabetes (PWT2D): A Systematic Literature Review and Network Meta-analysis

  • Description: No head-to-head studies compare daily Gla-300 vs weekly insulin Icodec. This analysis compared these two basal insulins in insulin-naïve PWT2D on OADs. MEDLINE®, Embase, and CENTRAL databases were searched on July 3, 2025 for RCTs evaluating once-daily Gla-300 or once-weekly Icodec in insulin-naïve PWT2D. Treatment effects at ~6 months were estimated using Bayesian and frequentist models.
  • Conclusion: In insulin-naïve PWT2D on OADs, Gla-300 was associated with lower level 1 and 2 hypoglycemia risk vs Icodec, with broadly comparable glycemic measures and overall safety at ~6 months.

MiRNA Abundance in Mesenchymal Stem Cells Exposed to Diabetes In Utero

  • Description: Mesenchymal stem cells (MSCs) from infants born to mothers with obesity and diabetes demonstrate increased adipogenic capacity, but the molecular mechanisms underlying this effect are unclear. The objective was to quantify changes in miRNA abundance in MSCs resulting from diabetes exposure and map their potential downstream pathways.
  • Conclusion: Specific differences in miRNA abundance, leading to circadian rhythm and epigenetic modifications, may be mechanisms underlying increased adipogenesis thereby placing offspring at risk for obesity and future metabolic disease.

Metabolic, Hepatic, Renal, and Hemodynamic Effects of DA-2811 vs. Forxiga in Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Study

  • Description: This study evaluated whether DA-2811 (DAPAPRO®, dapagliflozin formate) demonstrates effects comparable to FORXIGA® (dapagliflozin propanediol hydrate) on glycemic control as well as metabolic, hepatic, renal, and cardiovascular parameters in patients with type 2 diabetes mellitus (T2DM), which are recognized benefits of SGLT-2 inhibitors.
  • Conclusion: DA-2811 and FORXIGA® demonstrated comparable effects over 24-weeks across metabolic, hepatic, renal, and hemodynamic parameters in adults with T2DM, supporting similar clinical profiles for both formulations in routine practice.

Be sure to check out our recently published endocrinology content and sign up for alerts and stay informed on the latest published guidelines and articles.